Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States.
about
Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: study protocol for a pilot randomised controlled trialTreatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutideEfficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: a retrospective cohort studyAbdominal obesity is strongly associated with Cardiovascular Disease and its Risk Factors in Elderly and very Elderly Community-dwelling Chinese.Non-Persistence and Non-Adherence of Patients with Type 2 Diabetes Mellitus in Therapy with GLP-1 Receptor Agonists: A Retrospective Analysis.Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany.Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study.GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries.Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population.Glucagon-like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Naïve Patients with Type 2 Diabetes Mellitus: A Multinational Preference Study.Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom.Once-weekly exenatide as a treatment for Type 2 diabetes.Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus.Real-world comparison of treatment patterns and effectiveness of albiglutide and liraglutide.First novel once-weekly DPP-4 inhibitor, trelagliptin, for the treatment of type 2 diabetes mellitus.Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes.Rationale for treatment options for mealtime glucose control in patients with type 2 diabetes.Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia.Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once-weekly dipeptidyl peptidase-4 inhibitor, in healthy Japanese menPharmacokinetics and Pharmacodynamics of Omarigliptin, a Once-Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, After Single and Multiple Doses in Healthy Subjects.Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes.Treatment satisfaction with ITCA 650, a novel drug-device delivering continuous exenatide, versus twice-daily injections of exenatide in type 2 diabetics using metformin.Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease.Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece.Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement.
P2860
Q30489980-CD9F7139-928B-4069-8B94-048F6EA8FD3FQ33835762-AE709D44-51AA-402D-A709-0667F119A330Q33835897-0C3D73F2-1E06-4311-B1CE-3659C720644EQ35558388-95A7EF8D-B706-47D6-BD13-3139DEE632CDQ36587603-249435BF-462B-4FAC-8DA0-EE2675CD2C5EQ36712208-39A5F545-695D-4D71-9011-4D3CA0D51233Q37069371-A47666F2-9FBC-415E-96B7-B1093BCAF797Q37340216-38A17B26-AF92-4B9F-BFB8-C2A363359CD7Q37639316-DC876F88-F511-4BEC-AD14-F5052D0576D1Q37699685-C2FAF4D9-B42C-4656-ABA8-A2DEDE4ACD12Q37737456-3FE525E4-08D6-411F-B1E5-A0B359454105Q37737463-4F40E5D7-6383-4183-AD6B-6F7DE2DD98A1Q38497691-C6F22BD9-5ED7-4B38-B8FC-DEF4FAA65C9EQ38526870-ABD0DCBD-6B2A-4CA2-A803-4FDDEC42CEAFQ38621798-D1996792-B756-4C62-BDC8-B9964EC944DCQ38622203-A19D1C5B-82EB-4BB7-98AA-8F6CAE79D10EQ38708352-04F50512-4534-488C-9849-B31C70FF2FABQ39101008-750C62E4-8A17-4BF3-ACEC-6B6C0D8F8741Q39440767-5513D652-CD51-404F-9FF2-260B7D78DEE8Q40888889-187B2EE2-C872-4EA7-861C-0E442D00FB97Q42138923-62B10B5E-3E65-480A-8F1C-56F26EA7AC0BQ42371337-2AF85A68-0821-4F1F-8467-614B30E8F98EQ46519581-AE9AB10B-D7F1-4767-BD7E-88B9567418E6Q47404233-2FB26BD8-D794-4FBC-9E7E-164BEC912DFCQ47698045-E6A585BA-9A89-475B-B6A2-2841A0BF3D71Q53681732-CF742FFF-AF17-4303-9CD3-626C1C499A9D
P2860
Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Retrospective study of adheren ...... mellitus in the United States.
@en
Retrospective study of adheren ...... mellitus in the United States.
@nl
type
label
Retrospective study of adheren ...... mellitus in the United States.
@en
Retrospective study of adheren ...... mellitus in the United States.
@nl
prefLabel
Retrospective study of adheren ...... mellitus in the United States.
@en
Retrospective study of adheren ...... mellitus in the United States.
@nl
P2093
P2860
P1433
P1476
Retrospective study of adheren ...... mellitus in the United States.
@en
P2093
Bong-Chul Chu
Eugene Felber
Hiep Nguyen
Iftekhar Kalsekar
James K Nelson
Katherine Cappell
Stephen S Johnston
P2860
P2888
P304
P356
10.1007/S12325-014-0166-0
P407
P577
2014-11-19T00:00:00Z
P6179
1003535965